Image Place holder

Fernando Vargas, MD

Specialty: Hematology/Oncology
Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System


    Dr. Vargas received his MD from Universidad San Martin de Porres in Lima, Peru. He completed a residency in Internal Medicine at Albert Einstein Medical Center, followed by a fellowship in Hematology/Oncology at Jackson Memorial Hospital/University of Miami Miller School of Medicine. Dr. Vargas joins us from Pfizer, where he served as the Medical Director.     Dr. Vargas’s primary clinical interest is in the treatment of patients with hematologic malignancies, including leukemia, lymphoma and multiple myeloma. His research focuses on improving the outcomes of patients with acute myeloid and lymphoid leukemias through innovative clinical trials. He is also interested in cellular therapies and their applications in the treatment of patients with hematologic malignancies.    

Education & Training

Participating Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzomab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precusor B-cell ALL
Condition: Malignant Hematology
Open (affiliates only)

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Byrnes DM, Vargas F, Dermarkarian C, Kahn R, Kwon D, Hurley J, Schatz JH. Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients. J Oncol. 2019 May.2019:4047617. Pubmedid: 31186634. Pmcid: PMC6521528.
  • Vargas-Madueno F, Gould E, Valor R, Ngo N, Zhang L, Villalona-Calero MA. EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors. Oncologist. 2018 Oct.23(10):1127-1132. Pubmedid: 29739898. Pmcid: PMC6263129.
  • Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clin Lung Cancer. 2018 May.19(3):280-288.e4. Pubmedid: 29336998.
  • Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leuk Res. 2018 Jan.64:34-41. Pubmedid: 29175379. Pmcid: PMC5756519.
  • Swords R, Sznol J, Elias R, Watts J, Zelent A, Martin E, Vargas F, Bethel-Ellison S, Kobetz E. Acute leukemia in adult Hispanic Americans: a large-population study. Blood Cancer J. 2016 Oct.6(10):e484. Pubmedid: 27740629. Pmcid: PMC5098265.
  • Campuzano-Zuluaga G, Deutsch Y, Salzberg M, Gomez A, Vargas F, Elias R, Kwon D, Goodman M, Ikpatt OF, Chapman JR, Watts J, Vega F, Swords R. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?. Am J Hematol. 2016 Mar.91(3):277-282. Pubmedid: 26663264.
  • Davila CD, Vargas F, Huang KH, Monaco T, Dimou A, Rangaswami J, Figueredo VM. Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. Platelets. 2015 Dec.26(7):651-656. Pubmedid: 25354134.
  • Junpaparp P, Buppajarntham S, Madueno FV, Varadi G. Concomitant typhlitis and Clostridium difficile colitis developed after first R-CHOP chemotherapy in a non-Hodgkin lymphoma patient. BMJ Case Rep. 2013 Apr.2013. Pubmedid: 23598937. Pmcid: PMC3645077.

Patient Comments
Overall Satisfaction

patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments